Biphasic effects of the β-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle

British Journal of Pharmacology

Volumn 117, Issue 6, 1996, Pages 1355-1361

  Liu, Yong Ling ^a,b   Cawthorne, Michael A ^b   Stock, Michael J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BUCKINGHAM   (United Kingdom)

Author keywords

Atenolol; BRL 37344; CL 316,243; Glucose; Glycogen; ICI 118551; Skeletal muscle; adrenoceptors

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; DEOXYGLUCOSE; GLUCOSE; GLYCOGEN; INSULIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; MALE; MUSCLE METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; SOLEUS MUSCLE;

EID: 0029670070     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb16736.x     Document Type: Article

References (41)

1. 3-adrenergic agonist, BRL 35135A, on glucose uptake in rat skeletal muscle in vivo and in vitro. J. Endocrinol., 139, 479-486.
2. ARCH, J.R.S., AINSWORTH, A.T., CAWTHORNE, M.A., PIERCY, V., SENNIT, M.V., THODY, V., WILSON, C. & WILSON, S. (1984). Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature, 309, 163-165.
3. 3 and atypical β-adrenoceptors. Med Res. Rev., 13, 663-729.
4. BARON, A.D., STEINBERG, H., BRECHTEL, G. & JOHNSON, A. (1994). Skeletal muscle blood flow independently modulates insulin-mediated glucose uptake. Am. J. Physiol., 266, E248-E253.
5. 3adrenoceptor-mediated increase in cutaneous blood flow in the dog. J. Pharmacol. Exp. Ther., 268, 1444-1451.
6. BONEN, A.B., CLARK, M.G. & HENRIKSEN, E.J. (1994). Experimental approaches in muscle metabolism: hindlimb perfusion and isolated muscle incubations. Am. J. Physiol., 266, E1-E16.
7. CARTEE, G.D., YOUNG, D.A., SLEEPER, M.D., ZIERATH, J., WALLBER-HENRIKSSON, H. & HOLLOSZY, J.O. (1989). Prolonged increase in insulin-stimulated glucose transport in muscle after excercise. Am. J. Physiol., 256, E494-E499.
8. CAWTHORNE, M.A., SENNITT, M.V., ARCH, J.R.S. & SMITH, S.A. (1992). BRL 35135, a potent and selective atypical β-adrenoceptor agonist. Am. J. Clin. Nutr., 55, 252S-257S.
9. CHALLISS, R.A.J., LEIGHTON, B., WILSON, S., THURLBY, P. & ARCH, J. (1988). An investigation of the β-adrenoceptor that mediates metabolic responses to the novel agonist BRL 28410 in rat soleus muscle. Biochem. Pharmacol., 37, 947-950.
10. i in rat adipocytes. Cell. Signal., 6, 457-465.
11. 3-adrenergic receptor. Science, 245, 1118-1121.
12. FUKUMOTO, H., KAYANO, T., BUSE, J.B., EDWARDS, Y., PILCH, P.F., BELL, G.Z. & SEINO, S. (1989). Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues. J. Biol. Chem., 264, 7776-7779.
13. GOODYEAR, L.J., HIRSHMAN, M.F., SMITH, R.J. & HORTON, E.S. (1991). Glucose transporter number, activity and isoform content in plasma membranes of red and white skeletal muscle. Am. J. Physiol., 261, E556-E561.
14. 3 adrenergic receptor? Cell. Signal., 7, 9-15.
15. GRANNEMAN, J.G., LAHNERS, K.N. & CHAUDHRY, A. (1991). Molecular cloning and expression of the rat beta 3-adrenergic receptor. Mol. Pharmacol., 40, 895-899.
16. 3-adrenoceptor selective agonists in four adipocyte types. Eur. J. Pharmacol., 200, 325-330.
17. ISSAD, T., PENICAUD, L., FERRE, P., KANDE, J., BAUDON, M.A. & GIRARD, J. (1987). Effects of fasting on tissue glucose utilization in conscious resting rats. Biochem. J., 246, 241-244.
18. JAMES, D.E., STRUBE, M. & MUECKLER, M. (1989). Molecular cloning and characterization of an insulin-regulatable glucose transporter. Nature, 338, 83-87.
19. KLIP, A. & PÂQUET, M. (1990). Glucose transport and glucose transporters in muscles and their metabolic regulation. Diabetes Care, 13, 228-243.
20. KRIEF, S., LÖNNQVIST, F., RAIMBAULT, S., BAUDE, B., VAN SPRONSEN, A., ARNER, P., STROSBERG, A.D., RICQUIER, D. & EMORINE, L.J. (1993). Tissue distribution of beta 3-adrenergic receptor mRNA in man. J. Clin. Invest., 91, 344-449.
21. 3-adrenergic receptors parallels lipolysis in rat adipocytes. Biochim. Biophys. Acta, 1135, 349-352.
22. 3-adrenoceptor agonist (CL 316,243). Drug Develop. Res., 32, 69-76.
23. 3-adrenoceptor agonist, BRL 35135, on tissue glucose utilization. Br. J. Pharmacol., 114, 888-894.
24. 3-adrenoceptors) mediating relaxation in the rat distal colon in vitro. Eur. J. Pharmacol., 101, 569-574.
25. MILLIGAN, G. (1993). Mechanisms of multifunctional signalling by G protein-linked receptors. Trends Pharmacol. Sci., 14, 239-244.
26. 125I]cyanopindolol binding sites in rat skeletal muscle. Eur. J. Pharmacol., 209, 257-262.
27. 3-adrenoceptor-induced activation of cyclic AMP-dependent protein kinase with activation of lipolysis in rat white adipocytes. Biochem. Pharmacol., 46, 575-581.
28. PESSIN, J.E. & BELL, G.I. (1992). Mammalian facilitative glucose transporter family: structure and molecular regulation. Annu. Rev. Physiol., 54, 911-930.
29. 125I]-cyanopindolol binding sites in rat soleus muscle. Br. J. Pharmacol., 109, 344-352.
30. 3-adrenergic receptor stimulation in conscious dogs. J. Pharmacol. Exp. Ther., 268, 466-473.
31. SHIMAZU, T. (1994). Central nervous system regulation of energy expenditure in brown adipose tissue and skeletal muscle. Int. J. Obes., 18 (Suppl. 2), P147.
32. SILLENCE, M.N. & MATTHEWS, M.L. (1994). Classical and atypical binding sites for β-adrenoceptor ligands and activation of adenylyl cyclase in bovine skeletal muscle and adipose tissue membranes. Br. J. Pharmacol., 111, 866-872.
33. 3-adrenoceptors compared in brown adipose tissue and in skeletal muscle membranes. Br. J. Pharmacol., 109, 1157-1163.
34. SMITH, S.A., SENNITT, M.V. & CAWTHORNE, M.A. (1990). BRL 35135: an orally active antihyperglycaemic agent with weight reducing effects. In New Anti-diabetic Drugs. ed. Bailey, C.J. & Flatt, P.R. pp. 177-189. London: Smith-Gordon.
35. SUMMERS, R.J., RUSSELL, F.D., ROBERTS, S.J., BONAZZI, V.R., SHARKEY, A., EVANS, B.A. & MOLENAAR, P. (1995). Localization and characterization of atypical β-adrenoceptors in skeletal muscle and gut. Pharmacol. Commun., 6, 237-252.
36. TAKAHASHI, A., SUDO, M., MINOKOSHI, Y. & SHIMAZU, T. (1992). Effects of ventromedial hypothalamic stimulation on glucose transport system in rat tissues. Am. J. Physiol., 263, R1228-R1234.
37. THURLBY, P.L. & ELLIS, R.D.M. (1986). Differences between the effects of noradrenaline and the β-adrenoceptor agonist BRL21410 in brown adipose tissue and hind limb of the anaesthetized rat. Can. J. Physiol. Pharmacol., 64, 1111-1114.
38. VALLERAND, A.L., PERUSSE, F. & BUKOWIECKI, L.J. (1987). Cold exposure potentiates the effect of insulin on in vivo glucose uptake. Am. J. Physiol., 253, E179-E186.
39. WALLBERG-HENRIKSSON, H. & HOLLOSZY, J.O. (1985). Activation of glucose transport in diabetic muscle: responses to contraction and insulin. Am. J. Physiol., 249, C233-C237.
40. YEN, T.T. (1994). Antiobesity and antidiabetic β-agonists: lessons learned and questions to be answered. Obesity Res., 2, 472-480.
41. 3-adrenoceptor agonist, in yellow KK mice. Life Sci., 54, 491-498.